Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.

BACKGROUND The highly pharmacokinetic variability of tacrolimus makes it difficult to adjust the dose. In the current study, we investigated the influence of gene polymorphisms and other clinical factors on long-term tacrolimus dosing in Chinese renal transplant recipients. METHODS A total of 276 renal transplant recipients were enrolled. The tacrolimus trough concentration and other clinical variables were recorded for 5 years following transplantation. Eight single nucleotide polymorphisms in four genes (CYP3A5, CYP3A4, ABCB1, and NR1I2) were genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis and sequencing. The dose-adjusted tacrolimus trough concentrations were calculated and compared among patients according to allelic status. RESULTS The alleles CYP3A5*3 and CYP3A4*18B were significantly associated with dose-adjusted tacrolimus blood trough concentrations and had a strong time-genotype interaction with tacrolimus pharmacokinetics. NR1I2 g.7635A>G had a significant interaction with time, but the dose-adjusted tacrolimus concentration did not significantly differ over 5 years posttransplantation, except for the GG genotype of NR1I2 g.7635A>G. Sex differences had an important influence on tacrolimus concentration during the later post-transplantation period. CONCLUSIONS The interindividual variability of tacrolimus concentration appears to be due in part to the effects of these identified genetic variants and clinical characteristics. Thus, genotyping of the CYP3A4 and CYP3A5 genes should be considered with respect to determining tacrolimus dose regimens during the post-transplantation period.

[1]  Ze-Neng Cheng,et al.  Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5*3 genotype in Chinese renal transplant recipients , 2016, Acta Pharmacologica Sinica.

[2]  K. Aouam,et al.  Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. , 2015, Pharmacogenomics.

[3]  L. Wang,et al.  Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients. , 2015, Genetics and molecular research : GMR.

[4]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[5]  D. Tibboel,et al.  Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics , 2015, Clinical Pharmacokinetics.

[6]  M. Huang,et al.  Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. , 2015, Pharmacogenomics.

[7]  Xueding Wang,et al.  Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population , 2015, Acta Pharmacologica Sinica.

[8]  E. Coto,et al.  The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients , 2015, Journal of Human Genetics.

[9]  H. Xin,et al.  Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients. , 2014, International journal of clinical pharmacology and therapeutics.

[10]  A. Åsberg,et al.  The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients , 2014, European Journal of Clinical Pharmacology.

[11]  Ze-yan Zhong,et al.  Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients , 2014, PloS one.

[12]  A. Edefonti,et al.  Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients. , 2013, Pharmacogenomics.

[13]  Russ B Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.

[14]  M. Mikov,et al.  Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients. , 2011, Gender medicine.

[15]  Joo-Youn Cho,et al.  Effects of Pregnane X Receptor (NR1I2) and CYP2B6 Genetic Polymorphisms on the Induction of Bupropion Hydroxylation by Rifampin , 2011, Drug Metabolism and Disposition.

[16]  A. Barry,et al.  A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients , 2010, Therapeutic drug monitoring.

[17]  J. McElnay,et al.  Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. , 2009, British journal of clinical pharmacology.

[18]  Zheng Jiao,et al.  Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients , 2008, European Journal of Clinical Pharmacology.

[19]  M. Huang,et al.  A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. , 2007, Current drug metabolism.

[20]  H. Zhou,et al.  Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[22]  P. Beaune,et al.  Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  Lin He,et al.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci , 2005, Cell Research.

[24]  K. Budde,et al.  MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. , 2004, British journal of clinical pharmacology.

[25]  Kenichi Yoshida,et al.  Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter , 2003, Journal of Human Genetics.

[26]  C. Staatz,et al.  Population pharmacokinetics of tacrolimus in adult kidney transplant recipients , 2002, Clinical pharmacology and therapeutics.

[27]  J. Hudson,et al.  The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.

[28]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[29]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[30]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.